Citron Takes Aim at Mallinckrodt, Blasts Acthar Gel Medication
'Express Scripts has finally changed its stance on Acthar and the effect will send shares of Mallinckrodt to zero,' Citron said.

Shares of Mallinckrodt (MNK) were falling by 8.3% to $39.10 on heavy trading volume on Monday morning, after short seller Citron Research issued a new report criticizing the pharmaceutical company.

Citron went after the company's H.P. Acthar Gel, which is used to treat a variety of conditions, and the enormous price increases that have brought the drug up to almost $40,000 per vial.

Citron attacked Mallinckrodt's partnership with Express Scripts (ESRX) , liking it to the role specialty prescription company Philidor played for embattled pharma company Valeant (VRX) .

"While Express Scripts was supposed to protect the healthcare system from gouges like Acthar, they were actually distributing the drug through their CuraScript division," Citron claims.

However, now Express is changing its tune on Acthar Gel, claiming that the drug is overpriced and poor quality.

"Express Scripts has finally changed its stance on Acthar and the effect will send shares of Mallinckrodt to zero," Citron said.

Jim Cramer and Real Money columnists discuss the latest from President Donald Trump and the GOP's efforts to repeal and replace the Affordable Care Act. See which stocks they are discussing and get his insights or analysis with a free trial subscription to Real Money.

More from Stocks

Stocks End Close to Home

Stocks End Close to Home

General Electric CFO to TheStreet: In 'Wait and See' Mode When It Comes to Trade

General Electric CFO to TheStreet: In 'Wait and See' Mode When It Comes to Trade

Bonds vs. Stocks: What's the Difference?

Bonds vs. Stocks: What's the Difference?

Jim Cramer on Bank of America, Tariffs and the Goldman Sachs CEO Change

Jim Cramer on Bank of America, Tariffs and the Goldman Sachs CEO Change

Nvidia Is Taking Over the Autonomous Driving Industry -- Here's How

Nvidia Is Taking Over the Autonomous Driving Industry -- Here's How